Abstract
Plasma homocysteine and cysteine levels were measured in 90 patients with PD with the MTHFR C677T (T/T) genotype. The authors found that the levels of homocysteine-a possible risk factor for vascular disease-were elevated by 60% in levodopa-treated patients with PD, with the most marked elevation occurring in patients with the T/T genotype. Cysteine levels in subjects with PD did not differ from levels in control subjects. In the T/T genotype patients, homocysteine and folate levels were inversely correlated. Increased homocysteine might be related to levodopa, MTHFR genotype, and folate in PD.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Aged, 80 and over
-
Antiparkinson Agents / administration & dosage
-
Cysteine / blood
-
Female
-
Folic Acid / blood
-
Genotype
-
Homocysteine / blood*
-
Humans
-
Levodopa / administration & dosage
-
Male
-
Methylenetetrahydrofolate Reductase (NADPH2)
-
Middle Aged
-
Oxidoreductases Acting on CH-NH Group Donors / genetics*
-
Parkinson Disease / blood*
-
Parkinson Disease / drug therapy
-
Parkinson Disease / genetics*
-
Point Mutation*
Substances
-
Antiparkinson Agents
-
Homocysteine
-
Levodopa
-
Folic Acid
-
Oxidoreductases Acting on CH-NH Group Donors
-
Methylenetetrahydrofolate Reductase (NADPH2)
-
Cysteine